Introduction: What they say
What we say: [easy_payment currency=”USD”]
From the Significance of the study to Public health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over 80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From research findings to therapeutic opportunity:
This study suggests, for the first time, that SNAI1, by decreasing the expression of its target gene, it may suppress the expression of tumor suppressor and the ageing marker INK4a/p16. Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility. Thus, (1) By treating myocardial patients with SNAi1 activators, one may prevent Dilated cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) pharmacological formulations encompassing “SNAI1 activators“ may be used to inhibit dilated cardiomyopathy and heart failure.
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How SNAI1 suppresses the expression of tumor suppressor p16(INK4a).
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Cardiac rejuvenation therapy: SNAI1 , a positive regulator of epithelial-mesenchymal transitions, suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 30/November/2015, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com